Last reviewed · How we verify
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Details
| Lead sponsor | AbbVie |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 912 |
| Start date | Fri Jul 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Nov 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Atopic Dermatitis
Interventions
- Placebo for Upadacitinib
- Upadacitinib
Countries
Italy, Taiwan, Ireland, South Korea, Croatia, Denmark, New Zealand, Netherlands, Belgium, Bulgaria, Portugal, United States, France, Greece, Austria, Hungary, Canada, Spain, United Kingdom, Germany, Australia, Singapore, Czechia